The Mast Cell Axis: MCAS as Comorbidity vs. Comparator
MCAS in ME/CFS is estimated at 16.7–25.3% depending on diagnostic criteria. Under strict international consensus criteria, idiopathic MCAS prevalence falls to ~4.4% — fewer than 5% of patients suspected of MCAS meet stringent criteria. The MCAS diagnostic problem mirrors the ME/CFS diagnostic problem: a clinical syndrome defined by symptom patterns and exclusion with no validated biomarker, vulnerable to both overdiagnosis (attributing non-specific symptoms to a trendy diagnosis) and underdiagnosis (dismissing genuine mast cell pathology as “just ME/CFS”).
Consequence: MCAS’s status as a contested diagnosis within a contested diagnosis makes it a nosological hall of mirrors — the boundary between “ME/CFS patient with mast cell activation” and “MCAS patient with fatigue” depends on which criteria are applied and by whom.
Severity applicability: Unknown — mast cell mediator testing is rarely performed in severe/bedbound patients.
(Certainty: 0.40.) Four mechanistically distinct non-IgE pathways can trigger mast cell degranulation — MRGPRX2-mediated, complement C3a/C5a, lectin-IgE glycan cross-linking, and food additive/oxidative pathways. These pathways are not IgE-dependent and would not be detected by standard allergy testing, yet they provide mechanistic plausibility for the 68–70% food intolerance rate in ME/CFS.
The nosological significance: these pathways are condition-agnostic. MRGPRX2 activation by substance P (released during PEM) would trigger mast cells in ME/CFS, fibromyalgia, and Long COVID identically, regardless of the diagnostic label. The food-intolerance → mast cell → symptom pathway may be a downstream convergent mechanism shared across the contested diagnosis cluster, not an ME/CFS-specific feature.
Falsifiable prediction: A food challenge study in ME/CFS, fibromyalgia, and IBS patients will show equivalent post-prandial tryptase elevation and symptom exacerbation across conditions, with individual variability exceeding between-condition variability. If between-condition differences significantly exceed within-condition variability, the shared-pathway hypothesis is weakened.
Consequence: If mast cell activation is a cross-condition convergent mechanism, mast cell stabilizers (ketotifen, cromolyn) should show efficacy across multiple contested diagnoses, not just MCAS — predicting positive results in ME/CFS, fibromyalgia, and IBS trials, with individual response determined by baseline tryptase rather than by diagnosis.
Fewer than 5% of patients suspected of idiopathic MCAS meet strict consensus criteria. Not all ME/CFS symptom burden should be attributed to mast cells — fatigue, brain fog, and orthostatic intolerance have well-documented non-mast-cell mechanisms in ME/CFS. The clinical hazard: labelling every ME/CFS patient with food sensitivities as MCAS can lead to polypharmacy with mast cell stabilizers and antihistamines, some of which (particularly first-generation H1 antihistamines) have anticholinergic and sedating effects that worsen cognitive symptoms.
Consequence: MCAS and ME/CFS share a nosological hazard — both are contested diagnoses where diagnostic expansion (looser criteria capturing more patients) can improve recognition but dilute specificity and drive inappropriate treatment.